Literature DB >> 19779763

Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection.

Tomoyo Maeda1, Shogo Banno, Shinji Maeda, Taio Naniwa, Yoshihito Hayami, Maiko Watanabe, Rei Itoh, Shigeki Sato, Ryuzo Ueda.   

Abstract

We aimed to determine the sensitivity and specificity of QuantiFERON-TB Gold (QFT-G) in Japanese rheumatoid arthritis (RA) patients with a past history of tuberculosis (TB). We assessed whether it is possible to decrease the cutoff using receiver operating characteristic (ROC) analysis. We evaluated chest computed tomography (CT) findings, prior history of treatment, and contact with active TB in 370 RA patients. Forty-nine patients before initiation of treatment with tumor necrosis factor (TNF) inhibitors were divided into two groups: 22 with a past history of TB and 27 without. We estimated the efficacy of QFT-G compared with the tuberculin skin test and antituberculosis (anti-TB) glycolipid antigen antibody. QFT-G was positive (>or=0.35 IU/ml) in 13.6% with a past history of TB, increasing to 27.3% at the intermediate range cutoff of 0.1 IU/ml. The sensitivity and specificity of QFT-G was 0.27 and 1.00, respectively, at 0.1 IU/ml. Using ROC analysis, the area under the curve (AUC) of QFT-G but not for the other two tests was significantly large. QFT-G is a useful diagnostic method due to its superior specificity, but the use of a cutoff value of 0.35 IU/ml will likely result in an underestimate. We propose that a lower interferon-gamma (IFN-gamma) titer of 0.1 IU/ml be adopted when deciding to administer anti-TB drugs before initiation of TNF inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779763     DOI: 10.1007/s10165-009-0226-5

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  4 in total

1.  Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy.

Authors:  Akiko Kowada
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

2.  Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.

Authors:  José M Ramos; Mar Masiá; Juan C Rodríguez; Cristina López; Sergio Padilla; Catalina Robledano; Francisco J Navarro-Blasco; Jaime Matarredona; Mariana F García-Sepulcre; Félix Gutiérrez
Journal:  Clin Exp Med       Date:  2012-06-27       Impact factor: 3.984

3.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

4.  [Concordance between the test of the tuberculin and Interferon Gamma Release Assay-IGRA in patients with immune-mediated inflammatory diseases].

Authors:  I Pérez Catalán; C Roig Martí; M Gil Fortuño; P Torrent Ramos; P Albiol Viñals; M Carballido Fernández; R M Larrea; C Ortín Martín; J Usó Blasco; J M Ramos Rincón
Journal:  Rev Esp Quimioter       Date:  2019-09-16       Impact factor: 1.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.